4-54290331-C-G

Variant summary

Our verdict is Benign. Variant got -8 ACMG points: 1P and 9B. PP2BP4_StrongBP6BS2

The NM_006206.6(PDGFRA):ā€‹c.2899C>Gā€‹(p.Leu967Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000236 in 1,611,740 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. L967L) has been classified as Likely benign.

Frequency

Genomes: š‘“ 0.0013 ( 0 hom., cov: 33)
Exomes š‘“: 0.00012 ( 0 hom. )

Consequence

PDGFRA
NM_006206.6 missense

Scores

1
3
15

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:1B:3O:1

Conservation

PhyloP100: 3.00
Variant links:
Genes affected
PDGFRA (HGNC:8803): (platelet derived growth factor receptor alpha) This gene encodes a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family. These growth factors are mitogens for cells of mesenchymal origin. The identity of the growth factor bound to a receptor monomer determines whether the functional receptor is a homodimer or a heterodimer, composed of both platelet-derived growth factor receptor alpha and beta polypeptides. Studies suggest that this gene plays a role in organ development, wound healing, and tumor progression. Mutations in this gene have been associated with idiopathic hypereosinophilic syndrome, somatic and familial gastrointestinal stromal tumors, and a variety of other cancers. [provided by RefSeq, Mar 2012]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -8 ACMG points.

PP2
Missense variant in gene, where missense usually causes diseases (based on misZ statistic), PDGFRA. . Gene score misZ 1.9401 (greater than the threshold 3.09). Trascript score misZ 3.4078 (greater than threshold 3.09). GenCC has associacion of gene with congenital heart disease, polyps, multiple and recurrent inflammatory fibroid, gastrointestinal, gastrointestinal stromal tumor, isolated cleft palate.
BP4
Computational evidence support a benign effect (MetaRNN=0.008911014).
BP6
Variant 4-54290331-C-G is Benign according to our data. Variant chr4-54290331-C-G is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 135018.We mark this variant Likely_benign, oryginal submissions are: {not_provided=1, Likely_benign=1, Uncertain_significance=1, Benign=1}.
BS2
High AC in GnomAd4 at 204 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
PDGFRANM_006206.6 linkuse as main transcriptc.2899C>G p.Leu967Val missense_variant 22/23 ENST00000257290.10

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
PDGFRAENST00000257290.10 linkuse as main transcriptc.2899C>G p.Leu967Val missense_variant 22/231 NM_006206.6 P1P16234-1

Frequencies

GnomAD3 genomes
AF:
0.00134
AC:
204
AN:
152236
Hom.:
0
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.00475
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000392
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.000478
GnomAD3 exomes
AF:
0.000318
AC:
80
AN:
251258
Hom.:
0
AF XY:
0.000214
AC XY:
29
AN XY:
135782
show subpopulations
Gnomad AFR exome
AF:
0.00455
Gnomad AMR exome
AF:
0.000116
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.000326
GnomAD4 exome
AF:
0.000121
AC:
177
AN:
1459386
Hom.:
0
Cov.:
30
AF XY:
0.000106
AC XY:
77
AN XY:
726194
show subpopulations
Gnomad4 AFR exome
AF:
0.00446
Gnomad4 AMR exome
AF:
0.000157
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.0000116
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
9.01e-7
Gnomad4 OTH exome
AF:
0.000282
GnomAD4 genome
AF:
0.00134
AC:
204
AN:
152354
Hom.:
0
Cov.:
33
AF XY:
0.00128
AC XY:
95
AN XY:
74500
show subpopulations
Gnomad4 AFR
AF:
0.00474
Gnomad4 AMR
AF:
0.000392
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.00
Gnomad4 OTH
AF:
0.000473
Alfa
AF:
0.000540
Hom.:
0
Bravo
AF:
0.00157
ESP6500AA
AF:
0.00522
AC:
23
ESP6500EA
AF:
0.00
AC:
0
ExAC
AF:
0.000436
AC:
53

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:1Benign:3Other:1
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

Hereditary cancer-predisposing syndrome Uncertain:1Benign:1
Uncertain significance, criteria provided, single submitterclinical testingAmbry GeneticsOct 03, 2018The p.L967V variant (also known as c.2899C>G), located in coding exon 21 of the PDGFRA gene, results from a C to G substitution at nucleotide position 2899. The leucine at codon 967 is replaced by valine, an amino acid with highly similar properties. One study detected this alteration in a patient with a congenital diaphragmatic hernia (Bleyl SB et al. Eur. J. Hum. Genet., 2007 Sep;15:950-8). This variant has also been identified in a cohort of 681 ancestrally diverse, healthy subjects. (Bodian DL et al. PLoS ONE, 2014 Apr;9:e94554). This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Likely benign, criteria provided, single submittercurationSema4, Sema4Sep 10, 2020- -
PDGFRA-related disorder Benign:1
Likely benign, no assertion criteria providedclinical testingPreventionGenetics, part of Exact SciencesSep 13, 2022This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -
Gastrointestinal stromal tumor Benign:1
Benign, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpJan 29, 2024- -
not specified Other:1
not provided, no classification providedreference populationITMISep 19, 2013- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.060
BayesDel_addAF
Benign
-0.40
T
BayesDel_noAF
Benign
-0.35
CADD
Benign
23
DANN
Uncertain
1.0
DEOGEN2
Benign
0.036
.;T
Eigen
Benign
0.091
Eigen_PC
Uncertain
0.28
FATHMM_MKL
Pathogenic
0.98
D
LIST_S2
Uncertain
0.88
D;D
M_CAP
Benign
0.015
T
MetaRNN
Benign
0.0089
T;T
MetaSVM
Benign
-0.74
T
MutationAssessor
Benign
0.90
.;L
MutationTaster
Benign
0.99
N;D
PrimateAI
Benign
0.48
T
PROVEAN
Benign
0.29
N;N
REVEL
Benign
0.25
Sift
Benign
0.50
T;D
Sift4G
Benign
0.29
T;D
Polyphen
0.47
.;P
Vest4
0.46
MVP
0.30
MPC
0.070
ClinPred
0.016
T
GERP RS
5.9
Varity_R
0.34
gMVP
0.45

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs140943817; hg19: chr4-55156498; API